scholarly journals Bloodstream infection caused by Acinetobacter junii in a patient with acute lymphoblastic leukaemia after allogenic haematopoietic cell transplantation

2011 ◽  
Vol 60 (3) ◽  
pp. 375-377 ◽  
Author(s):  
Rodrigo Cayô ◽  
Lucrecia Yañez San Segundo ◽  
Inmaculada Concepción Pérez del Molino Bernal ◽  
Celia García de la Fuente ◽  
Maria Aranzazu Bermúdez Rodríguez ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Bloodstream Infection ◽  
Clinical Significance ◽  
Lymphoblastic Leukaemia ◽  
Transplant Patient ◽  
Paediatric Oncology ◽  
Correct Identification ◽  
Human Pathogen ◽  
Acinetobacter Junii ◽  
Haematopoietic Cell

Acinetobacter junii is a rare human pathogen associated with bacteraemia in neonates and paediatric oncology patients. We present a case of A. junii causing bacteraemia in an adult transplant patient with leukaemia. The correct identification of Acinetobacter species can highlight the clinical significance of the different species of this genus.

scholarly journals Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts

2017 ◽  
Vol 178 (4) ◽  
pp. 583-587 ◽  
Author(s):  
Monica Messina ◽  
Sabina Chiaretti ◽  
Anna Lucia Fedullo ◽  
Alfonso Piciocchi ◽  
Maria Cristina Puzzolo ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Clinical Significance ◽  
Lymphoblastic Leukaemia ◽  
Copy Number ◽  
Fusion Genes ◽  
Age Cohorts ◽  
Copy Number Aberrations ◽  
B Lineage

scholarly journals What are the volume and budget needs to provide chemotherapy to all children with acute lymphoblastic leukaemia in Thailand? Development and application of an estimation tool

BMJ Open ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. e041901
Author(s):  
Rosarin Sruamsiri ◽  
Alessandra Ferrario ◽  
Dennis Ross-Degnan ◽  
Avram E Denburg ◽  
A Lindsay Frazier ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Outcome Measures ◽  
Lymphoblastic Leukaemia ◽  
Treatment Guidelines ◽  
Paediatric Oncology ◽  
Essential Medicines ◽  
Secondary Outcome ◽  
Major Barrier ◽  
The Difference ◽  
Treat All

ObjectiveInsufficient access to anticancer medicines may contribute to the wide survival differences of children with cancers across the globe. We developed a tool to estimate the volume of medicines and budget requirements to provide chemotherapy to children with acute lymphoblastic leukaemia (ALL).DesignDevelopment and application of an estimation tool.SettingPaediatric oncology hospital departments in Thailand.Participants318 children aged 0–14 years diagnosed with ALL and 215 children with undiagnosed ALL.InterventionsEstimates of volume and budget requirements for administering a full course of chemotherapy for ALL and a further course for children who relapse, according to National Treatment Guidelines.Primary and secondary outcome measuresPrimary outcome measures were the volume (mg) and cost (US$) of medicines needed to treat children with ALL. For medicines whose main indication is paediatric ALL (asparaginase and 6-mercaptopurine), we estimated the difference between volume needed and actual sales in 2017 (secondary outcome).ResultsTen anticancer medicines and four chemoprotective agents are needed for the treatment of paediatric ALL according to the Thai treatment guidelines. Of these 14 medicines, 13 are included in the WHO essential medicines list for children. All are available as generics. We estimated that essential chemotherapy and chemoprotective agents to treat all children diagnosed with ALL in Thailand in 2017 would cost US$ 814 952 (US$ 1 365 422 for diagnosed and undiagnosed children), which corresponds to 0.005% (0.008%) of the country’s total health expenditure. The volumes of asparaginase and 6-mercaptopurine available on the Thai market in 2017 were more than sufficient (2.3 and 1.5 times the amounts needed, respectively) to treat all children diagnosed with ALL.ConclusionsProcuring sufficient quantities of essential medicines to treat children with ALL requires relatively modest resources. Medicine cost should not be a major barrier to ALL treatment in similar settings.

scholarly journals Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion

ESMO Open ◽  
2020 ◽  
Vol 5 (5) ◽  
pp. e000977
Author(s):  
André Baruchel ◽  
Patrick Brown ◽  
Carmelo Rizzari ◽  
Lewis Silverman ◽  
Inge van der Sluis ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Expert Panel ◽  
Panel Discussion ◽  
Paediatric Oncology ◽  
Therapeutic Drug ◽  
Childhood Acute Lymphoblastic Leukaemia ◽  
Leukemic Relapse ◽  
Life Threatening ◽  
The Impact

Insufficient exposure to asparaginase therapy is a barrier to optimal treatment and survival in childhood acute lymphoblastic leukaemia (ALL). Three important reasons for inactivity or discontinuation of asparaginase therapy are infusion related reactions (IRRs), pancreatitis and life-threatening central nervous system (CNS). For IRRs, real-time therapeutic drug monitoring (TDM) and premedication are important aspects to be considered. For pancreatitis and CNS thrombosis one key question is if patients should be re-exposed to asparaginase after their occurrence.An expert panel met during the Congress of the International Society for Paediatric Oncology in Lyon in October 2019 to discuss strategies for diminishing the impact of these three toxicities. The panel agreed that TDM is particularly useful for optimising asparaginase treatment and that when a tight pharmacological monitoring programme is established premedication could be implemented more broadly to minimise the risk of IRR. Re-exposure to asparaginase needs to be balanced against the anticipated risk of leukemic relapse. However, more prospective data are needed to give clear recommendations if to re-expose patients to asparaginase after the occurrence of severe pancreatitis and CNS thrombosis.

Sign in / Sign up

Export Citation Format

Share Document